CRBU
NASDAQ
US
Caribou Biosciences, Inc. - Common Stock
$1.94
▼ $-0.05
(-2.51%)
Vol 1.1M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$148.6M
ROE
-80.8%
Margin
-1690.5%
D/E
0.00
Beta
2.68
52W
$1–$4
Wall Street Consensus
15 analysts · Apr 20265
Strong Buy
9
Buy
1
Hold
0
Sell
0
Strong Sell
93.3%
Buy Rating
Price Chart
Similar Stocks
ANIK
Anika Therapeutics Inc
$138.6M
SABS
SAB Biotherapeutics Inc
P/E 9.5
$178.0M
ELTX
Elicio Therapeutics Inc
$139.2M
ZNTL
Zentalis Pharmaceuticals Inc
$97.5M
MGNX
MacroGenics Inc
$101.8M
TNXP
Tonix Pharmaceuticals Holding Corp
$199.7M
CRBP
Corbus Pharmaceuticals Holdings Inc
$142.9M
GALT
Galectin Therapeutics Inc
$268.2M
ACHV
Achieve Life Sciences Inc
$264.6M
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.32 | $-0.28 | +$0.04 |
| Sep 2025 | $-0.37 | $-0.30 | +$0.07 |
| Jun 2025 | $-0.40 | $-0.58 | $-0.18 |
| Mar 2025 | $-0.45 | $-0.43 | +$0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $2.1M | $2.4M | $2.7M | $2.2M | $3.9M |
| Net Income | — | -$35.5M | -$40.0M | -$54.1M | -$27.5M | -$26.5M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -71.6% | -71.6% | -71.6% | -71.6% | -80.8% | -80.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -2028.4% | -1800.9% | -1800.9% | -1800.9% | -1690.5% | -1690.5% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.66 | 6.66 | 6.66 | 6.66 | 5.54 | 5.54 |
Key Ratios
ROA (TTM)
-62.7%
P/S (TTM)
15.99
P/B
0.6
EPS (TTM)
$-1.70
CF/Share
$-1.36
Rev Growth 3Y
+1.4%
52W High
$3.54
52W Low
$0.66
$0.66
52-Week Range
$3.54
Financial Health
Free Cash Flow
-$20.6M
Net Debt
$14.9M
Cash
$12.4M
Total Debt
$27.2M
As of Dec 31, 2025
How does CRBU compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CRBU valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
16.0
▲
24%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.6
▼
77%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CRBU profitability vs Biotechnology peers
ROE
-80.8%
▼
20%
below
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-1690.5%
▼
490%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-62.7%
▼
34%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
CRBU financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
5.5
▲
25%
above
peers
(4.4)
vs Peers
vs Industry
Below avg
Beta
2.7
▲
177%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
CRBU fundamentals radar
CRBU
Peer median
Industry
CRBU profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CRBU vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
KELLY TIMOTHY P
Chief Technology Officer · Feb 25
6228 shs
MCCLUNG BARBARA G
Officer · Feb 24
6938 shs
KELLY TIMOTHY P
Chief Technology Officer · Feb 24
3147 shs
KHAN RUHI AHMAD
Officer · Feb 24
6938 shs
ALBERTSON TINA M.
Officer · Feb 24
1066 shs
MCCLUNG BARBARA G
Officer · Feb 20
45000 shs
HAURWITZ RACHEL E. PH.D.
Chief Executive Officer · Feb 20
151700 shs
KELLY TIMOTHY P
Chief Technology Officer · Feb 20
45000 shs
RYALI SRIRAM
Chief Financial Officer · Feb 20
55000 shs
KHAN RUHI AHMAD
Officer · Feb 20
45000 shs
Last 90 days
Top Holders
Top 5: 15.81%Pfizer Inc
4.85%
$8.3M
Vanguard Group Inc
4.45%
$7.7M
Kynam Capital Management, LP
2.59%
$4.5M
Blackrock Inc.
2.22%
$3.8M
Renaissance Technologies, L…
1.70%
$2.9M
As of Dec 31, 2025
Latest News
No related news yet